High cytoplasmic pARS515 was also associated with biochemical relapse (proportion of patients relapsed at 5 years 78.6% vs 56%) HR 2.15 (95% CI 1.1 4.2), P=0.02 (Table 5).
No associations were observed between the kinases and time to biochemical relapse; however, high nuclear AR was associated with biochemical relapse (proportion of patients relapsed at 5 years 79.2% vs 46.9%) HR 2.8 (95% CI 1.5 5.3), P=0.001, as was high total AR (proportion of patients relapsed at 5 years 85.1% vs 40.2%) HR 3.03 (95% CI 1.6 5.6), P<0.001.
The relapse proportions in the radiotherapy and combination arms were 81.4% (70 out of 86) and 69.2% (54 out of 78), respectively.
At 2 years, no significant differences in clinical outcomes (risk of relapse, ARR, proportion of relapse-free patients, and time to confirmed disability progression) or most MRI measures (including mean change in T1-hypointense lesion volume, and mean change in brain volume from baseline) were observed between any two treatment groups [ 43].
The results based on these PT cohorts were similar to those observed with the 'prescribed at study entry' groups using adjusted relapse rates (proportion of participants [95%; CI], PT-olanzapine [n = 57] versus PT-CMS [n = 121], 46.8%; [19.1%; to 76.6%;] vs 56.9%; [30.6%; to 79.9%;]; hazard ratio 0.765 [0.425 to 1.378]).
The best validated surrogate marker for relapse is the proportion of sputum cultures that remain positive after about 2 months of chemotherapy.
Both doses of FTY720 delayed the time to the first relapse, decreased the proportion of patients with confirmed relapses, and decreased the number of new MRI lesions and volume of contrast-enhancing lesions (Table 2).
A pre-specified integrated analysis of DEFINE and CONFIRM was conducted to assess DMF's effects on end-points including annualized relapse rate (ARR), proportion of patients relapsed, disability as measured by 12-week confirmed Expanded Disability Status Scale (EDSS) progression, number of gadolinium-enhancing (Gd+) lesions and number of T2 lesions, at 2 years [ 6].
Approximately 10% of individuals with CFS may improve for periods of at least a year, with a proportion relapsing intermittently [ 10, 11].
The Kaplan-Meier estimate of the proportion relapsed at 12 months was 41%95%5% confidence interval 29%to5353%) in the quetiapine group and 79% (68% to 90%) in the placebo group (χ=15.65, df=1; P<0.001 by log-rank) (fig 2).
The hazard ratio shows the proportion of relapse rates of predicted-relapse and predicted-RFS patients).
